03:26 PM EST - Helix BioPharma Corp. : Announced that it will initiate a new clinical program in pancreatic cancer which will be led by Dr. Daniel D. Von Hoff. Dr. Von Hoff is Physician-in-Chief at the Translational Genomics Research Institute and Professor of Medicine at both the Mayo Clinic and the University of Arizona College of Medicine. Helix BioPharma Corp.
shares T.HBP are trading up $0.01 at $0.51.
